Adicet Bio appoints Michael Grissinger to Board; Carl Gordon resigns

Adicet Bio, Inc.

Carl L. Gordon resigned from Board and Compensation Committee effective April 17, 2025; no disagreement with management.
Michael Grissinger appointed to Board and Compensation Committee, effective April 17, 2025, as Class II director until 2026 annual meeting.
Grissinger received option to purchase 70,200 shares at April 17 closing price, vesting over 36 months.
Grissinger brings 40+ years pharma experience, including 20+ years at Johnson & Johnson leading immunology licensing and M&A.
He also serves on boards of Aprea Therapeutics (APRE) and three private biotechs.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Michael Grissinger

Director

ACET · Adicet Bio, Inc.

Effective: 2025-04-17
Filed: April 17, 2025, 7:59 PM ET

On April 16, 2025, upon the recommendation of the Nominating and Corporate Governance Committee of the Board, the Board appointed Michael Grissinger to the Board, effective as of April 17, 2025, to fill the vacancy resulting from Dr. Gordon’s resignation.

Departed

Carl L. Gordon

Director

ACET · Adicet Bio, Inc.

Effective: 2025-04-17
Successor: Michael Grissinger
Filed: April 17, 2025, 7:59 PM ET

On April 14, 2025, Carl L. Gordon, Ph.D., a Class II member of the board of directors (the “Board”) of Adicet Bio, Inc. (the “Company”), notified the Company of his resignation from the Board and Compensation Committee of the Board (the “Compensation Committee”), effective on April 17, 2025.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Michael Grissinger was appointed as Director at Adicet Bio, Inc..

Action: appointed
Role: Director

Exact text from the filing

On April 16, 2025, upon the recommendation of the Nominating and Corporate Governance Committee of the Board, the Board appointed Michael Grissinger to the Board, effective as of April 17, 2025, to fill the vacancy resulting from Dr. Gordon’s resignation.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Carl L. Gordon resigned as Director at Adicet Bio, Inc..

Action: resigned
Role: Director

Exact text from the filing

On April 14, 2025, Carl L. Gordon, Ph.D., a Class II member of the board of directors (the “Board”) of Adicet Bio, Inc. (the “Company”), notified the Company of his resignation from the Board and Compensation Committee of the Board (the “Compensation Committee”), effective on April 17, 2025.

View on SEC.gov

Adicet Bio, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-25-054995

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.